Guidelines to the management of epistaxis

B-ENT

Volumn 1, Issue SUPPL. 1, 2005, Pages 27-41

  Bertrand, Bernard ^a,b,e   Eloy, Ph ^a,b   Rombaux, Ph ^a,b   Lamarque, C ^c   Watelet, J B ^d   Collet, S ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c Clinique St Luc Bouge   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

Conservative treatment; Cost analysis; Endoscopic surgery; Epistaxis; Management; Medical treatment; Nose bleeding; Surgery

Indexed keywords

AC17; ACETYLSALICYLIC ACID; BATROXOBIN; CARBAZOCHROME; CARBAZOCHROME SODIUM SULFONATE; COLESTYRAMINE; CONJUGATED ESTROGEN; ESTROGEN; ETAMSYLATE; GUANETHIDINE; LIDOCAINE; MENADIOL SODIUM PHOSPHATE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDIZED REGENERATED CELLULOSE; OXYMETAZOLINE; PHENOTHIAZINE; PHYTOMENADIONE; PSEUDOMONIC ACID; SEMICARBAZONE; SNAKE VENOM; SULFACETAMIDE; TERLIPRESSIN; TETRACAINE; THROMBIN; TRANEXAMIC ACID; VITAMIN K GROUP; WARFARIN;

BLOOD CLOTTING DISORDER; BLOOD DYSCRASIA; CATHETER; CHEMICAL COMPOSITION; CLINICAL FEATURE; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG POTENTIATION; EPISTAXIS; GAUZE DRESSING; GRANULOMATOSIS; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; INFLAMMATION; INJURY; INTOXICATION; MEDLINE; MORBIDITY; OTORHINOLARYNGOLOGY; PATHOPHYSIOLOGY; PERFORATION; PRACTICE GUIDELINE; REVIEW; SCURVY; SEPSIS; TUMOR; VASCULAR DISEASE; COST BENEFIT ANALYSIS; PROGNOSIS;

COST-BENEFIT ANALYSIS; EPISTAXIS; HUMANS; PROGNOSIS;

EID: 33644876994     PISSN: 1781782X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Résultats de l'Observatoire français de l'épistaxis. Revue Officielle de la Société Française d'O.R.L. 2002;75:62-67.
2. Juselius H. Epistaxis. A clinical study of 1,724 patients. J Laryngol Otol 1974;88:317-327.
3. Doyle DE. Anterior epistaxis: a new nasal tampon for fast, effective control. Laryngoscope. 1986;96:279-281.
4. McGarry GW, Gatehouse S, Vernham G. Idiopathic epistaxis, haemostasis and alcohol. Clin Otolaryngol. 1995;20:174-177.
5. Carlos CC, Oishi K, Cinco MT, et al. Comparison of clinical features and hematologic abnormalities between Dengue fever and Dengue hemorrhagic fever among children in the Philippines. Am J Trop Med Hyg. 2005;73:435-440.
6. Sureau PH. Firsthand clinical observations of hemorrhagic manifestations in Ebola hemorrhagic fever in Zaire. Rev Infect Dis. 1989;11 Suppl 4:8790-793.
7. Sandoval C, Dong S, Visintainer P, Ozkaynak MF, Jayabose S. Clinical and laboratory features of 178 children with recurrent epistaxis. J Pediatr Hematol Oncol. 2002;24:47-49.
8. Beran, M, B. Petruson. Occurrence of epistaxis in habitual nose- bleeders and analysis of some etiological factors. ORL J Otorhinolaryngol Relat Spec. 1986;48:297-303.
9. Lubianca Neto JF, Fuchs FD, Facco SR, et al. Is epistaxis evidence of end-organ damage in patients with hypertension? Laryngoscope. 1999;109:1111-1115.
10. Herkner H, Laggner AN, Mullner M, et al., Hypertension in patients presenting with epistaxis. Ann Emerg Med. 2000;35:126-130.
11. Padgham N. Epistaxis: anatomical and clinical correlates. J Laryngol Otol. 1990;104:308-311.
12. Temmel AF, Quint C, Toth J. Debate about blood pressure and epistaxis will continue. BMJ. 2001;322:1181.
13. Manfredini R, Portaluppi F, Salmi R, Martini A, Gallerani M. Circadian variation in onset of epistaxis: analysis of hospital admissions. BMJ. 2000;321:1112.
14. Vaghela HM. Using a swimmer's nose clip in the treatment of epistaxis in the A&E department. Accid Emerg Nurs. 2005;29. [Epub ahead of print]
15. Murthy P, Nilssen EL, Rao S, McClymont LG. A randomized clinical trial of antiseptic nasal carrier cream and silver nitrate cautery in the treatment of recurrent anterior epistaxis. Clin Otolaryngol Allied Sci. 1999;24:228-231.
16. Lloyd S, Almeyda J, Di Cuffa R, Shah K. The effect of silver nitrate on nasal septal cartilage. Ear Nose Throat J. 2005;84:41-44.
17. O'Donnell M, Robertson G, McGarry GW. A new bipolar diathermy probe for the outpatient management of adult acute epistaxis. Clin Otolaryngol Allied Sci. 1999;24:537-541.
18. Thornton MA, Mahesh BN, Lang J. Posterior epistaxis: identification of common bleeding sites. Laryngoscope. 2005;115:588-590.
19. Mathiasen RA, Cruz RM. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in patients with acute anterior epistaxis. Laryngoscope. 2005;115:899-902.
20. Chandra RK, Conley DB, Kern RC. The effect of FloSeal on mucosal healing after endoscopic sinus surgery: a comparison with thrombin-soaked gelatin foam. Am J Rhinol. 2003;17:51-55.
21. Makura ZG, Porter GC, Mac Cornick MS. Pediatric epistaxis: Alder Hey experience. J Laryngol Otol. 2002;116:903-906.
22. Derkay CS, Hirsch BE, Johnson JT, Wagner RL. Posterior nasal packing. Are intravenous antibiotics really necessary? Arch Otolaryngol Head neck Surg. 1989;115:439-441.
23. Walshe P, Harkin C, Murphy S, Shah C, Curran A, McShane D. The use of fibrin glue in refractory coagulopathic epistaxis. Clin Otolaryngol Allied Sci. 2001;26:284-285.
24. Strong EB, Bell DA, Johnson LP, Jacobs JM. Intractable epistaxis: transantral ligation vs. embolization: efficacy review and cost analysis. Otolaryngol Head Neck Surg. 1995;113:674-678.
25. Maceri DR, Makielski KH. Intraoral ligation of the maxillary artery for posterior epistaxis. Laryngoscope. 1984;94:737-741.
26. Snyderman CH, Goldman SA, Carrau RL, Ferguson BJ, Grandis JR. Endoscopic sphenopalatine artery ligation is an effective method of treatment for posterior epistaxis. Am J Rhinol. 1999;13:137-140.
27. O'Flynn PE, Shadaba A. Management of posterior epistaxis by endoscopic clipping of the sphenopalatine artery. Clin Otolaryngol Allied Sci. 2000;25:374-347.
28. Ram B, White PS, Saleh HA, Odutoye T, Cain A. Endoscopic endonasal ligation of the sphenopalatine artery. Rhinology. 2000;38:147-149.
29. Wormanld PJ, Wee DT, van Hasselt CA. Endoscopic ligation of the sphenopalatine artery for refractory posterior epistaxis. Am J Rhinol. 2000;14:261-264.
30. Scaramuzzi N, Walsh RM, Brennan P, Walsh M. Treatment of intractable epistaxis using arterial embolization. Clin Otolaryngol Allied Sci. 2001;26:307-309.
31. Rockey JG, Anand R. A critical audit of the surgical management of intractable epistaxis using sphenopalatine artery ligation/diathermy. Rhinology. 2002;40:147-149.
32. Woolford TJ, Jones NS. Endoscopic ligation of anterior ethmoidal artery in treatment of epistaxis. J Laryngol Otol. 2000;114:858-860.
33. Elahi MM, Parnes LS, Fox AJ, Pelz DM, Lee DH. Therapeutic Embolization in the Treatment of Intractable Epistaxis. Arch Otolaryngol Head Neck Surg. 1995;121:65-69.
34. Moreau S, De Rugy MG, Babin E, Courtheoux P, Valdazo A. Supraselective Embolization in Intractable Epistaxis: Review of 45 Cases. Laryngoscope. 1998;108:887-888.
35. Tseng EY, Narducci CA, Willing SJ, Sillers MJ. Angiographic embolization for epistaxis: a review of 114 cases. Laryngoscope. 1998;108:615-659.
36. Romagnoli M, Marina R, Sordo L, Gaini RM. Indications for selective arterial embolization in the treatment of epistaxis. Acta Otorhinolayngol Ital. 2000;20:330-335.
37. Oguni T, Korogi Y, Yasunaga T, et al. Superselective embolization for intractable idiopathic epistaxis. Br J Radiol. 2000;73:1148-1153.
38. Lund VJ, Howard DJ. A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol. 1999;13:319-322.
39. Mahoney EJ, Shapshay SM. Nd-YAG laser photocoagulation for epistaxis associated with hereditary hemorrhagic telangiectasia. Laryngoscope. 2005;115:373-375.
40. Karapantzos I, Tsimpiris N, Goulis DG, Van Hoecke H, Van Cauwenberge P, Danielides V. Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire. Eur Arch Otorhinolaryngol. 2005;1. [Epub ahead of print]
41. Bergler W, Sadick H, Gotte K, Riedel F, Hormann K. Topical estrogens combined with argon plasma coagulation in the management of epistaxis in HHT. Ann Otl Rhinol Laryngol. 2002;111:222-228.
42. Farnan TB, Gallagher G, Scally CM. A novel treatment for patients with hereditary haemorragic telengiectasia. J Laryngol Otol. 2002;116:849-850.
43. Hitchings AE, Lennox PA, Lund VJ, Howard DJ. The effect of treatment for epistaxis secondary to hereditary hemorrhagic telangiectasia. Am J Rhinol. 2005;19:75-78.
44. Woolford TJ, Loke D, Bateman ND. The use of a nasal obturator in hereditary haemorragic telangiectasia: an alternative to Young's procedure. J Laryngol Otol. 2002;116:455-456.
45. Jameson JJ, Cave DR. Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 2004;114:705-709.
46. Simmen D, Heinz B. Epistaxis strategy-experiences with the last 360 hospitalizations. Laryngorhinootologie 1998;77:100-106.
47. Goddard JC, Reiter ER. Inpatient management of epistaxis: outcomes and cost. Otolaryngol Head Neck Surg. 2005;132:707-712.
48. Moshaver A, Harris JR, Liu R, Diamond C, Seikaly H. Early operative intervention versus conventional treatment in epistaxis: randomized prospective trial. J Otolaryngol. 2004;33:185-188.
49. Miller TR, Stevens ES, Orlandi RR. Economic analysis of the treatment of posterior epistaxis. Am J Rhinol. 2005;191:79-82.
50. Peele JC. Control of hemorrhage from the nose and throat. Med Times. 1958;86:1228-1237.
51. Peele JC. Further observations on the use of adrenosem salicylate in the control of hemorrhage from the nose and throat. N C Med J. 1956;17:98-103.
52. Peele JC. Adrenosem in the control of hemorrhage from the nose and throat; a preliminary report. AMA Arch Otolaryngol. 1955;61:450-464.
53. Meunier A, Agostini J, Sultan A, Deligne. The antihemorrhagic qualities of dicynone. Its advantages in O. R. L. [in French]. Ann Otolaryngol Chir Cervicofac. 1966;83:446-451.
54. Vinayak BC, Birchall MA, Donovan B, Stafford ND. A randomized double-blind trial of glypressin in the management of acute epistaxis. Rhinology. 1993;31:131-134.
55. Bende M, Pipkorn U. Topical terlipressin (Glypressin) gel reduces nasal mucosal blood flow but leaves ongoing nose-bleeding unaffected. Acta otolaryngol 1990;110:124-127.
56. White A, O'Reilly BF. Oral tranexamic acid in the management of epistaxis. Clin Otolaryngol. 1988;13:11-16.
57. Tibbelin A, Aust R, Bende M, et al. Effect of tranexamic acid gel in the treatment of epistaxis. ORL J Otorhinolaryngol Relat Spec. 1995;57:207-209.
58. Viducich RA, Blanda MP, Gerson LW. Posterior epistaxis: clinical features and acute complications. Ann Emerg Med. 1995;25:592-596.
59. Barlow DW, Deleyiannis WB, Pinczower EF. Effectiveness of surgical management of epistaxis at a tertiary care center. Laryngoscope. 1997;107:21-24.
60. Anand VK. Practical Endoscopic Sinus Surgery. McGraw-Hill, Inc., New York; 1993.
61. Bailey BJ. Head & Neck Surgery - Otolaryngology. Lippincott, Philadelphia; 2001.
62. King HC. A Practical Guide to the Management of Nasal and Sinus Disorders. Thieme Medical Publishers Inc., New York; 1993.
63. Marks SC. Nasal and Sinus Surgery. Saunders, Philadelphia; 2000.
64. Navarro JAC. The Nasal Cavity and Paranasal Sinuses. Springer-Verlag, Berlin; 2001.
65. Abelson TI: Epistaxis. In: Schaefer SD, ed. Rhinology and Sinus Disease. 1st ed. Mosby, New York; 1998:43-50.
66. Emanuel JM: Epistaxis. In: Cummings CW, ed. Otolaryngology-Head and Neck Surgery. 3rd ed. Mosby, St. Louis; 1998:852-865.
67. McQueen CT, DiRuggiero DC, Campbell JP, Shockley WW. Orbital osteology: a study of the surgical landmarks. Laryngoscope. 1995;105:783-788.